# Diffuse large B-cell lymphoma

Source: https://onco.cc/cancers/dlbcl/  
OnCo record `dlbcl` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved.

## Summary

Diffuse large B-cell lymphoma is the most common aggressive lymphoma, about 30% of all non-Hodgkin lymphoma, with a median age around 65. It is curable: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) cures roughly 60% of patients, more with low IPI and fewer with high-risk features (IPI 3-5, double-hit MYC/BCL2 rearrangement, activated B-cell origin, TP53 loss). Staging uses PET-CT and the Lugano classification; biology is read from cell of origin and FISH for MYC, BCL2 and BCL6, with genetic classifiers (LymphGen) and ctDNA emerging.

Frontline therapy stood still for twenty years until POLARIX (2022) showed that replacing vincristine with the CD79b ADC polatuzumab vedotin improves progression-free survival (5-year 64.9% vs 59.1%), and frontMIND (Lancet 2026) showed tafasitamab plus lenalidomide added to R-CHOP improves PFS in IPI 3-5 disease (HR 0.75); epcoritamab plus R-CHOP (EPCORE DLBCL-2) and golcadomide plus R-CHOP (GOLSEEK-1) follow. For the 30-40% who relapse, the sequence has been rebuilt around T-cell redirection: CD19 CAR-T (axi-cel, liso-cel) beats salvage chemotherapy and transplant for relapse within a year (ZUMA-7 with an overall survival benefit; TRANSFORM), while transplant remains for later chemosensitive relapse. Off-the-shelf CD20×CD3 bispecifics (glofitamab, epcoritamab, mosunetuzumab, odronextamab) give complete remissions in about 40% of heavily pretreated patients, and chemotherapy-free doublets such as mosunetuzumab-polatuzumab (SUNMO) beat salvage chemotherapy. CD19 ADC (loncastuximab), tafasitamab-lenalidomide, and the ROR1 ADC zilovertamab vedotin fill later lines.

The open questions are regulatory as much as scientific. EPCORE DLBCL-1 (2026) improved PFS but not overall survival against chemotherapy; STARGLO's survival benefit was rejected by the FDA because the trial was mostly enrolled in Asia. Nobody has compared bispecifics with CAR-T head to head. ctDNA (PhasED-seq) predicts cure better than PET and is the obvious tool for response-adapted frontline therapy. Primary refractory disease, CNS relapse, older and frail patients, and access to CAR-T outside major centres remain the hard problems.

## Fields

- Kind: Cancer
- Last checked: 2026-09-07
- Tags: heme; spike
- Group: haematologic
- Burden: ~150,000 new cases a year worldwide; ~25,000 in the US; median age 65; about 60% cured with first-line therapy.
- Subtypes: Germinal-centre B-cell-like (GCB) vs activated B-cell-like (ABC / non-GCB); High-grade B-cell lymphoma with MYC and BCL2 rearrangements (double hit); LymphGen genetic subtypes: MCD, BN2, N1, EZB, ST2, A53; Primary mediastinal B-cell lymphoma (distinct; PD-1 responsive); Primary CNS lymphoma (distinct; methotrexate-based); Transformed indolent lymphoma (Richter, transformed follicular); EBV-positive DLBCL of the elderly; Primary refractory vs early relapse (<12 months) vs late relapse
- Biomarkers: Cell of origin (GCB/ABC); Double-hit (MYC/BCL2); CD19/CD20; ctDNA MRD; IPI / NCCN-IPI; Cell of origin (Hans IHC, Lymph2Cx); MYC, BCL2, BCL6 FISH; TP53 mutation; CD19 and CD20 expression (loss after CAR-T or bispecific); Interim and end-of-treatment PET (Deauville); ctDNA (PhasED-seq, clonoSEQ); LDH; CNS-IPI for CNS prophylaxis decisions

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/dlbcl/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/dlbcl/#overview [1 subtype, 7 state-of-the-art points]
- What it is (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/dlbcl/#what-it-is [9 subtypes]
- Finding it (on the hub): How it shows itself, how it is confirmed, what screening exists, and the biomarkers clinicians test for. https://onco.cc/cancers/dlbcl/#finding-it [13 biomarkers, 8 prevalence rows]
- Treating it (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/dlbcl/#treating-it [11 settings, 7 regimens, 9 decisions with options]
- Evidence (own page): Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/dlbcl/evidence/ [87 trials, 7 key papers, 19 milestones]
- The science (own page): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/dlbcl/science/ [120 targets, 5 pathways, 10 preclinical models]
- Where you are (own page): Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record. https://onco.cc/cancers/dlbcl/where-you-are/ [61 centres]
- Living with it (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/dlbcl/#living-with-it [33 questions, 6 red cards]
- What is coming (own page): Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/dlbcl/coming/ [61 medicines, 87 trials, 18 ideas, 10 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/dlbcl/data/ [544 connected records]

## Standard of care

- Frontline: R-CHOP or Pola-R-CHP.
- Early relapse: CD19 CAR-T. ([Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/))
- Later: CD20×CD3 bispecifics, loncastuximab, tafasitamab. ([Glofitamab](https://onco.cc/drugs/glofitamab/), [Loncastuximab tesirine](https://onco.cc/drugs/zynlonta/))
- Limited stage (I-II, non-bulky): R-CHOP × 4 with PET-guided omission of radiation (FLYER, S1001): 4 cycles if interim PET negative; involved-site radiotherapy if PET positive. ([Doxorubicin](https://onco.cc/drugs/doxorubicin/), [FDG PET](https://onco.cc/technologies/fdg-pet/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Lugano classification / Ann Arbor staging](https://onco.cc/terms/lugano-classification/))
- Advanced stage, IPI 0-1: R-CHOP × 6 (or Pola-R-CHP); consider 4 cycles plus 2 rituximab in young low-risk patients (FLYER). ([Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Polatuzumab vedotin](https://onco.cc/drugs/polatuzumab-vedotin/), [International Prognostic Index (IPI)](https://onco.cc/terms/ipi-score/))
- Advanced stage, IPI 2-5: Pola-R-CHP × 6 (POLARIX) or R-CHOP × 6; tafasitamab + lenalidomide + R-CHOP (frontMIND) pending approval for IPI 3-5; DA-EPOCH-R for double-hit lymphoma; CNS prophylaxis for high CNS-IPI (contested). ([POLARIX](https://onco.cc/trials/polarix/), [Polatuzumab vedotin](https://onco.cc/drugs/polatuzumab-vedotin/), [frontMIND](https://onco.cc/trials/frontmind/), [Tafasitamab](https://onco.cc/drugs/tafasitamab/), [Double-hit / high-grade B-cell lymphoma](https://onco.cc/terms/double-hit-lymphoma/))
- Frail or elderly: R-mini-CHOP; epcoritamab-based regimens in trials for the elderly (EPCORE NHL-2 cohorts); tafasitamab-lenalidomide where transplant is never an option. ([Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Tafasitamab](https://onco.cc/drugs/tafasitamab/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/))
- Primary refractory or relapse within 12 months: CD19 CAR-T (axi-cel or liso-cel) preferred over salvage chemotherapy and transplant (ZUMA-7, TRANSFORM); bridging therapy while manufacturing; bispecific ± chemotherapy if CAR-T unavailable. ([Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [ZUMA-7](https://onco.cc/trials/zuma-7/), [TRANSFORM](https://onco.cc/trials/transform/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/))
- Late relapse (>12 months), transplant-eligible: Salvage chemotherapy (R-ICE, R-DHAP, R-GemOx) → high-dose therapy and autologous transplant if chemosensitive; CAR-T if not. ([Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/))
- Relapse, transplant-ineligible: CD20×CD3 bispecific (glofitamab, epcoritamab) or mosunetuzumab-polatuzumab (SUNMO); pola-BR; tafasitamab-lenalidomide; loncastuximab tesirine. ([Glofitamab](https://onco.cc/drugs/glofitamab/), [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Mosunetuzumab](https://onco.cc/drugs/mosunetuzumab/), [Polatuzumab vedotin](https://onco.cc/drugs/polatuzumab-vedotin/), [Tafasitamab](https://onco.cc/drugs/tafasitamab/), [Loncastuximab tesirine](https://onco.cc/drugs/zynlonta/), [SUNMO](https://onco.cc/trials/sunmo/))
- Third line and beyond: CAR-T if not yet given; bispecific after CAR-T (active in CD19-negative relapse if CD20 retained); loncastuximab; zilovertamab vedotin (trial); allogeneic transplant in selected fit patients; clinical trials. ([Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [Glofitamab](https://onco.cc/drugs/glofitamab/), [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Loncastuximab tesirine](https://onco.cc/drugs/zynlonta/), [Zilovertamab vedotin](https://onco.cc/drugs/zilovertamab-vedotin/), [waveLINE-003](https://onco.cc/trials/waveline-003/))

## State of the art

- CAR-T second line.
- Bispecifics as off-the-shelf T-cell therapy.
- Frontline has moved: Pola-R-CHP (POLARIX) is standard for IPI 2-5, and frontMIND (tafasitamab-lenalidomide-R-CHOP) is the first phase 3 to beat R-CHOP in IPI 3-5 disease since rituximab.
- CD19 CAR-T is second-line standard for early relapse, with an overall survival benefit in ZUMA-7 (4-year OS 54.6% vs 46.0%).
- Four CD20×CD3 bispecifics approved or conditionally approved worldwide give ~40% complete remissions off the shelf; chemotherapy-free doublets (mosun-pola) beat salvage chemotherapy.
- ctDNA by phased-variant sequencing detects residual lymphoma below PET sensitivity and is entering response-adapted trials.
- Regulators now scrutinise generalisability (STARGLO CRL) and demand overall survival for confirmatory bispecific trials (EPCORE DLBCL-1 missed OS).

## Open problems

- Primary refractory disease.
- CAR-T access and cost.
- Primary refractory disease (~10-15%) still has poor outcomes even with CAR-T; CD19-negative and CD20-negative escape after targeted therapy.
- No head-to-head comparison of bispecifics and CAR-T; sequencing is by access rather than evidence.
- Overall survival is hard to demonstrate for bispecifics against chemotherapy with crossover and effective later lines (EPCORE DLBCL-1).
- Trial generalisability: STARGLO's rejection shows regional enrolment can decide approvals.
- CNS relapse: prophylaxis with high-dose methotrexate is of uncertain benefit and CNS-penetrant options are few.
- Older and frail patients are underrepresented; R-mini-CHOP cure rates lag and cellular therapies carry toxicity.
- Cost and access: CAR-T requires certified centres; bispecific CRS management needs infrastructure; lenalidomide-based triplets add expense.
- Response-adapted therapy: interim PET is unreliable and ctDNA is not yet a regulatory endpoint.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma
- Wikipedia: https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma

## Connected records

- pairings: [Caution: cumulative anthracycline dose and the heart](https://onco.cc/pairings/doxorubicin-cardio-caution/), [CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab)](https://onco.cc/pairings/bispecific-plus-adc-lymphoma/), [Early relapse: CAR-T before transplant](https://onco.cc/pairings/car-t-before-transplant-lbcl/)
- collections: [Leukemia & Lymphoma Society (LLS)](https://onco.cc/collections/leukemia-lymphoma-society/), [Lymphoma Research Foundation (LRF)](https://onco.cc/collections/lymphoma-research-foundation/)
- cancers: [Advanced-stage classical Hodgkin lymphoma (stage III to IV)](https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/), [Burkitt leukaemia](https://onco.cc/cancers/burkitt-leukaemia/), [Burkitt lymphoma](https://onco.cc/cancers/burkitt-lymphoma/), [Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)](https://onco.cc/cancers/malt-lymphoma/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [HIV-associated (AIDS-related) lymphomas](https://onco.cc/cancers/hiv-associated-lymphoma/), [Intravascular large B-cell lymphoma](https://onco.cc/cancers/intravascular-large-b-cell-lymphoma/), [Lymphomatoid granulomatosis](https://onco.cc/cancers/lymphomatoid-granulomatosis/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Marginal zone lymphoma](https://onco.cc/cancers/marginal-zone-lymphoma/), [Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)](https://onco.cc/cancers/angioimmunoblastic-t-cell-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/), [Post-transplant lymphoproliferative disorder (PTLD)](https://onco.cc/cancers/post-transplant-lymphoproliferative-disorder/), [Primary CNS lymphoma](https://onco.cc/cancers/primary-cns-lymphoma/), [Primary cutaneous follicle centre lymphoma](https://onco.cc/cancers/primary-cutaneous-follicle-centre-lymphoma/), [Primary mediastinal (thymic) large B-cell lymphoma](https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/), [Relapsed and refractory classical Hodgkin lymphoma](https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/)
- technologies: [Allogeneic cell banks: one donor, hundreds of doses](https://onco.cc/technologies/allogeneic-cell-banks/), [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/), [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Biosimilar manufacturing and comparability](https://onco.cc/technologies/biosimilar-manufacturing/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [CD47 and SIRP-alpha blockade](https://onco.cc/technologies/cd47-blockade/), [ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)](https://onco.cc/technologies/ctdna-lymphoma-monitoring/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Ex vivo drug sensitivity screening in blood cancers (EXALT)](https://onco.cc/technologies/functional-precision-medicine-haematology/), [Exercise during chemotherapy and radiotherapy](https://onco.cc/technologies/exercise-during-chemotherapy/), [FDG PET](https://onco.cc/technologies/fdg-pet/), [G8 geriatric screening tool](https://onco.cc/technologies/g8-geriatric-screening/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [In situ vaccination](https://onco.cc/technologies/in-situ-vaccination/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [NK cell therapy and CAR-NK](https://onco.cc/technologies/nk-cell-therapy/), [PET-adapted (response-adapted) therapy](https://onco.cc/technologies/pet-adapted-therapy/), [Photobiomodulation (low-level laser) for oral mucositis](https://onco.cc/technologies/photobiomodulation-mucositis/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/), [Strain echocardiography (global longitudinal strain)](https://onco.cc/technologies/strain-echocardiography-gls/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [Troponin and natriuretic peptide monitoring during cancer treatment](https://onco.cc/technologies/cardiac-biomarker-monitoring/), [Virus-specific T cells](https://onco.cc/technologies/virus-specific-t-cells/)
- targets: [ACTB](https://onco.cc/targets/actb/), [B2M](https://onco.cc/targets/b2m/), [BAX](https://onco.cc/targets/bax/), [BCL-2](https://onco.cc/targets/bcl2/), [BCL10](https://onco.cc/targets/bcl10/), [BCL11A](https://onco.cc/targets/bcl11a/), [BCL11B](https://onco.cc/targets/bcl11b/), [BCL6](https://onco.cc/targets/bcl6/), [BCL7A](https://onco.cc/targets/bcl7a/), [BIM (BCL2L11)](https://onco.cc/targets/bim/), [BTG1](https://onco.cc/targets/btg1/), [BTG2](https://onco.cc/targets/btg2/), [BTK (Bruton tyrosine kinase)](https://onco.cc/targets/btk/), [CCND3](https://onco.cc/targets/ccnd3/), [CCR7](https://onco.cc/targets/ccr7/), [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/), [CD22](https://onco.cc/targets/cd22/), [CD27](https://onco.cc/targets/cd27/), [CD28](https://onco.cc/targets/cd28/), [CD3](https://onco.cc/targets/cd3/), [CD30](https://onco.cc/targets/cd30/), [CD3D](https://onco.cc/targets/cd3d/), [CD3G](https://onco.cc/targets/cd3g/), [CD47](https://onco.cc/targets/cd47/), [CD58](https://onco.cc/targets/cd58/), [CD79b](https://onco.cc/targets/cd79b/), [CD83](https://onco.cc/targets/cd83/), [CDC50A](https://onco.cc/targets/cdc50a/), [CIITA](https://onco.cc/targets/ciita/), [DGCR8](https://onco.cc/targets/dgcr8/), [DOT1L](https://onco.cc/targets/dot1l/), [DTX1](https://onco.cc/targets/dtx1/), [DUSP2](https://onco.cc/targets/dusp2/), [EBF1](https://onco.cc/targets/ebf1/), [ETS1](https://onco.cc/targets/ets1/), [Exportin-1 (XPO1)](https://onco.cc/targets/xpo1/), [EZH2](https://onco.cc/targets/ezh2/), [FAS](https://onco.cc/targets/fas/), [FHIT](https://onco.cc/targets/fhit/), [FOXO1](https://onco.cc/targets/foxo1/), [Glucocorticoid receptor (NR3C1)](https://onco.cc/targets/glucocorticoid-receptor/), [Glutathione reductase](https://onco.cc/targets/gsr/), [GNA13](https://onco.cc/targets/gna13/), [GRHPR](https://onco.cc/targets/grhpr/), [H1-2](https://onco.cc/targets/h1-2/), [H1-3](https://onco.cc/targets/h1-3/), [H1-5](https://onco.cc/targets/h1-5/), [H2AC17](https://onco.cc/targets/h2ac17/), [H2AC6](https://onco.cc/targets/h2ac6/), [H2BC12](https://onco.cc/targets/h2bc12/), [H2BC5](https://onco.cc/targets/h2bc5/), [H3C2](https://onco.cc/targets/h3c2/), [HLA-B](https://onco.cc/targets/hla-b/), [HLA-C](https://onco.cc/targets/hla-c/), [HVCN1](https://onco.cc/targets/hvcn1/), [ID3](https://onco.cc/targets/id3/), [IKZF1 (Ikaros)](https://onco.cc/targets/ikzf1/), [IKZF3 (Aiolos)](https://onco.cc/targets/ikzf3/), [IL4R](https://onco.cc/targets/il4r/), [IRF4](https://onco.cc/targets/irf4/), [IRF8](https://onco.cc/targets/irf8/), [ITPKB](https://onco.cc/targets/itpkb/), [KLF2](https://onco.cc/targets/klf2/), [KLHL14](https://onco.cc/targets/klhl14/), [KLHL6](https://onco.cc/targets/klhl6/), [LTB](https://onco.cc/targets/ltb/), [MALT1](https://onco.cc/targets/malt1/), [MEF2B](https://onco.cc/targets/mef2b/), [MEF2C](https://onco.cc/targets/mef2c/), [MGA](https://onco.cc/targets/mga/), [MPEG1](https://onco.cc/targets/mpeg1/), [MYD88](https://onco.cc/targets/myd88/), [NFKB2](https://onco.cc/targets/nfkb2/), [NFKBIA](https://onco.cc/targets/nfkbia/), [NFKBIE](https://onco.cc/targets/nfkbie/), [NFKBIZ](https://onco.cc/targets/nfkbiz/), [NOL9](https://onco.cc/targets/nol9/), [OSBPL10](https://onco.cc/targets/osbpl10/), [P2RY8](https://onco.cc/targets/p2ry8/), [PABPC1](https://onco.cc/targets/pabpc1/), [PAX5](https://onco.cc/targets/pax5/), [PIM1](https://onco.cc/targets/pim1/), [PIM2](https://onco.cc/targets/pim2/), [POU2AF1](https://onco.cc/targets/pou2af1/), [POU2F2](https://onco.cc/targets/pou2f2/), [PRDM1](https://onco.cc/targets/prdm1/), [PRKCB](https://onco.cc/targets/prkcb/), [PRKDC](https://onco.cc/targets/prkdc/), [PTPN6](https://onco.cc/targets/ptpn6/), [RASA2](https://onco.cc/targets/rasa2/), [RBM38](https://onco.cc/targets/rbm38/), [REL](https://onco.cc/targets/rel/), [RMI2](https://onco.cc/targets/rmi2/), [ROR1](https://onco.cc/targets/ror1/), [S1PR2](https://onco.cc/targets/s1pr2/), [SETD1B](https://onco.cc/targets/setd1b/), [SGK1](https://onco.cc/targets/sgk1/), [SIN3A](https://onco.cc/targets/sin3a/), [SOCS1](https://onco.cc/targets/socs1/), [STAT3](https://onco.cc/targets/stat3/), [STAT6](https://onco.cc/targets/stat6/), [TBL1XR1](https://onco.cc/targets/tbl1xr1/), [TBX3](https://onco.cc/targets/tbx3/), [TCL1A](https://onco.cc/targets/tcl1a/), [TMSB4X](https://onco.cc/targets/tmsb4x/), [TNFAIP3](https://onco.cc/targets/tnfaip3/), [TNFRSF14](https://onco.cc/targets/tnfrsf14/), [Topoisomerase II alpha (TOP2A)](https://onco.cc/targets/top2a/), [TOX](https://onco.cc/targets/tox/), [UBE2A](https://onco.cc/targets/ube2a/), [Xanthine oxidase (XDH)](https://onco.cc/targets/xdh/), [ZFP36L1](https://onco.cc/targets/zfp36l1/), [ZNF292](https://onco.cc/targets/znf292/)
- drugs: [Abexinostat](https://onco.cc/drugs/abexinostat/), [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [ALLO-647](https://onco.cc/drugs/allo-647/), [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [AZD0486](https://onco.cc/drugs/azd0486/), [BGB-16673](https://onco.cc/drugs/bgb-16673/), [Carmustine](https://onco.cc/drugs/carmustine/), [clonoSEQ](https://onco.cc/drugs/clonoseq/), [CRC01](https://onco.cc/drugs/crc01/), [CTX112](https://onco.cc/drugs/ctx112/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [DZD8586](https://onco.cc/drugs/dzd8586/), [Emapalumab](https://onco.cc/drugs/emapalumab/), [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Etoposide](https://onco.cc/drugs/etoposide/), [Fostamatinib](https://onco.cc/drugs/fostamatinib/), [Glofitamab](https://onco.cc/drugs/glofitamab/), [Golcadomide](https://onco.cc/drugs/golcadomide/), [HMPL-760](https://onco.cc/drugs/hmpl-760/), [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Ifupinostat](https://onco.cc/drugs/ifupinostat/), [JNJ-90014496](https://onco.cc/drugs/jnj-90014496/), [KRT-232](https://onco.cc/drugs/krt-232/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Lisocabtagene maraleucel](https://onco.cc/drugs/lisocabtagene-maraleucel/), [Loncastuximab tesirine](https://onco.cc/drugs/zynlonta/), [Methotrexate](https://onco.cc/drugs/methotrexate/), [MK-1045](https://onco.cc/drugs/mk-1045/), [Mosunetuzumab](https://onco.cc/drugs/mosunetuzumab/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Odronextamab](https://onco.cc/drugs/odronextamab/), [Palifermin](https://onco.cc/drugs/palifermin/), [Parsaclisib](https://onco.cc/drugs/parsaclisib/), [Pirtobrutinib](https://onco.cc/drugs/pirtobrutinib/), [Pixantrone](https://onco.cc/drugs/pixantrone/), [Plerixafor](https://onco.cc/drugs/plerixafor/), [Polatuzumab vedotin](https://onco.cc/drugs/polatuzumab-vedotin/), [Prednisone](https://onco.cc/drugs/prednisone/), [Purinostat](https://onco.cc/drugs/purinostat/), [Rasburicase](https://onco.cc/drugs/rasburicase/), [Relmacabtagene autoleucel](https://onco.cc/drugs/relmacabtagene-autoleucel/), [Rituximab](https://onco.cc/drugs/rituximab/), [Rocbrutinib](https://onco.cc/drugs/rocbrutinib/), [Rondecabtagene autoleucel](https://onco.cc/drugs/rondecabtagene-autoleucel/), [Sargramostim](https://onco.cc/drugs/sargramostim/), [SCTB35](https://onco.cc/drugs/sctb35/), [Selinexor](https://onco.cc/drugs/selinexor/), [SHR-A1912](https://onco.cc/drugs/shr-a1912/), [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/), [Tafasitamab](https://onco.cc/drugs/tafasitamab/), [Talicabtagene autoleucel](https://onco.cc/drugs/talicabtagene-autoleucel/), [TC011](https://onco.cc/drugs/tc011/), [Tisagenlecleucel](https://onco.cc/drugs/tisagenlecleucel/), [TQB2825](https://onco.cc/drugs/tqb2825/), [Varnimcabtagene autoleucel](https://onco.cc/drugs/varnimcabtagene-autoleucel/), [Vincristine](https://onco.cc/drugs/vincristine/), [Zamtocabtagene autoleucel](https://onco.cc/drugs/zamtocabtagene-autoleucel/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/), [Zilovertamab vedotin](https://onco.cc/drugs/zilovertamab-vedotin/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/), [ADC Therapeutics](https://onco.cc/companies/adc-therapeutics/), [Allogene Therapeutics](https://onco.cc/companies/allogene/), [Angiocrine Bioscience](https://onco.cc/companies/angiocrine-bioscience/), [Antengene](https://onco.cc/companies/antengene/), [Araris Biotech (Taiho)](https://onco.cc/companies/araris/), [BeBetter Med](https://onco.cc/companies/bebetter-med/), [Biogen](https://onco.cc/companies/biogen/), [Bristol Myers Squibb](https://onco.cc/companies/bms/), [CARGO Therapeutics](https://onco.cc/companies/cargo-therapeutics/), [Caribou Biosciences](https://onco.cc/companies/caribou/), [Cellectis](https://onco.cc/companies/cellectis/), [Cellogen Therapeutics](https://onco.cc/companies/cellogen/), [Data Driven Bioscience (Duoseq)](https://onco.cc/companies/data-driven-bioscience/), [Denovo Biopharma](https://onco.cc/companies/denovo-biopharma/), [Fate Therapeutics](https://onco.cc/companies/fate-therapeutics/), [Foghorn Therapeutics](https://onco.cc/companies/foghorn-therapeutics/), [Foresight Diagnostics](https://onco.cc/companies/foresight-diagnostics/), [Genmab](https://onco.cc/companies/genmab/), [German Lymphoma Alliance](https://onco.cc/companies/german-lymphoma-alliance/), [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/), [HOVON](https://onco.cc/companies/hovon/), [Immuneel Therapeutics](https://onco.cc/companies/immuneel/), [ImmunoACT](https://onco.cc/companies/immunoact/), [Immunovaccine (IMV)](https://onco.cc/companies/immunovaccine/), [Imugene](https://onco.cc/companies/imugene/), [Incyte](https://onco.cc/companies/incyte/), [Indapta Therapeutics](https://onco.cc/companies/indapta-therapeutics/), [Interius BioTherapeutics](https://onco.cc/companies/interius/), [International Extranodal Lymphoma Study Group](https://onco.cc/companies/ielsg/), [Kartos Therapeutics](https://onco.cc/companies/kartos-therapeutics/), [LEAH Labs](https://onco.cc/companies/leah-labs/), [Lupeng Pharmaceuticals](https://onco.cc/companies/lupeng-pharmaceuticals/), [Lyell Immunopharma](https://onco.cc/companies/lyell-immunopharma/), [LYSA (The Lymphoma Study Association)](https://onco.cc/companies/lysa/), [Mabion](https://onco.cc/companies/mabion/), [Marker Therapeutics](https://onco.cc/companies/marker-therapeutics/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/), [Miltenyi Biomedicine](https://onco.cc/companies/miltenyi-biomedicine/), [ModeX Therapeutics](https://onco.cc/companies/modex-therapeutics/), [MorphoSys (Novartis)](https://onco.cc/companies/morphosys/), [Nkarta](https://onco.cc/companies/nkarta/), [Nordic Lymphoma Group](https://onco.cc/companies/nordic-lymphoma-group/), [Novartis](https://onco.cc/companies/novartis/), [Nurix Therapeutics](https://onco.cc/companies/nurix/), [Poseida Therapeutics](https://onco.cc/companies/poseida-therapeutics/), [Ranok Therapeutics (Hangzhou)](https://onco.cc/companies/ranok-therapeutics-hangzhou/), [Regeneron](https://onco.cc/companies/regeneron/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/), [Sana Biotechnology](https://onco.cc/companies/sana-biotechnology/), [Sinocelltech](https://onco.cc/companies/sinocelltech/), [Treeline Biosciences](https://onco.cc/companies/treeline-biosciences/), [Umoja Biopharma](https://onco.cc/companies/umoja-biopharma/), [Vironexis Biotherapeutics](https://onco.cc/companies/vironexis-biotherapeutics/)
- institutions: [Advanced Centre for Treatment, Research and Education in Cancer](https://onco.cc/institutions/actrec/), [American Society of Hematology](https://onco.cc/institutions/ash/), [Barts Cancer Institute / Barts Health NHS Trust](https://onco.cc/institutions/barts-cancer-institute/), [BC Cancer](https://onco.cc/institutions/bc-cancer/), [Butaro Cancer Center of Excellence](https://onco.cc/institutions/butaro-cancer-center/), [Cancer Institute AP-HP Nord, Université Paris Cité](https://onco.cc/institutions/aphp-nord-cancer-institute/), [Centre Henri Becquerel](https://onco.cc/institutions/centre-henri-becquerel/), [Charlotte Maxeke Johannesburg Academic Hospital / University of the Witwatersrand](https://onco.cc/institutions/wits-charlotte-maxeke/), [Chinese PLA General Hospital](https://onco.cc/institutions/pla-general-hospital/), [Cleveland Clinic Abu Dhabi](https://onco.cc/institutions/cleveland-clinic-abu-dhabi/), [Comprehensive Cancer Center Mainfranken, University Hospital Würzburg](https://onco.cc/institutions/ccc-wuerzburg/), [Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH](https://onco.cc/institutions/ccc-vienna/), [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/), [European Hematology Association](https://onco.cc/institutions/eha/), [Fred & Pamela Buffett Cancer Center](https://onco.cc/institutions/nebraska-buffett/), [Geneva University Hospitals (HUG)](https://onco.cc/institutions/hug-geneva/), [Gustave Roussy](https://onco.cc/institutions/gustave-roussy/), [Hadassah Medical Center](https://onco.cc/institutions/hadassah/), [Hamad Medical Corporation / National Center for Cancer Care and Research](https://onco.cc/institutions/hamad-medical-corporation/), [Henan Cancer Hospital](https://onco.cc/institutions/henan-cancer-hospital/), [Herbert Irving Comprehensive Cancer Center, Columbia University](https://onco.cc/institutions/columbia-hicc/), [HUS Comprehensive Cancer Center, Helsinki University Hospital](https://onco.cc/institutions/helsinki-hus/), [Institut Jules Bordet](https://onco.cc/institutions/institut-jules-bordet/), [Instituto Nacional de Cancerología (Mexico)](https://onco.cc/institutions/incan-mexico/), [IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola](https://onco.cc/institutions/sant-orsola-bologna/), [IRCCS Humanitas Research Hospital](https://onco.cc/institutions/humanitas/), [Keio University Hospital](https://onco.cc/institutions/keio-university-hospital/), [Kenyatta National Hospital](https://onco.cc/institutions/kenyatta-national-hospital/), [King Faisal Specialist Hospital and Research Centre](https://onco.cc/institutions/kfshrc/), [King Hussein Cancer Center](https://onco.cc/institutions/khcc/), [Koo Foundation Sun Yat-Sen Cancer Center](https://onco.cc/institutions/koo-foundation-sun-yat-sen-cancer-center/), [Kyushu University Hospital](https://onco.cc/institutions/kyushu-university-hospital/), [Leeds Cancer Centre, St James's University Hospital](https://onco.cc/institutions/leeds-cancer-centre/), [Max Delbrück Center for Molecular Medicine](https://onco.cc/institutions/mdc-berlin/), [Max Healthcare (Max Institute of Cancer Care)](https://onco.cc/institutions/max-healthcare/), [Mayo Clinic](https://onco.cc/institutions/mayo-clinic/), [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/), [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/), [Narayana Health (Mazumdar Shaw Medical Centre)](https://onco.cc/institutions/narayana-health/), [National Cancer Institute, Cairo University](https://onco.cc/institutions/nci-cairo/), [National University Hospital / National University Cancer Institute, Singapore](https://onco.cc/institutions/nuh-ncis/), [NCI Center for Cancer Research (intramural programme)](https://onco.cc/institutions/nci-ccr/), [Oncology Institute of Southern Switzerland (IOSI)](https://onco.cc/institutions/iosi-bellinzona/), [Peking University Cancer Hospital](https://onco.cc/institutions/pku-cancer-hospital/), [Rajiv Gandhi Cancer Institute and Research Centre](https://onco.cc/institutions/rgci/), [Rigshospitalet, Copenhagen University Hospital](https://onco.cc/institutions/rigshospitalet/), [Ruijin Hospital, Shanghai Jiao Tong University](https://onco.cc/institutions/ruijin-hospital/), [Seoul St. Mary's Hospital](https://onco.cc/institutions/seoul-st-marys-hospital/), [Sheba Medical Center](https://onco.cc/institutions/sheba/), [Tata Medical Center, Kolkata](https://onco.cc/institutions/tata-medical-center-kolkata/), [The Christie NHS Foundation Trust](https://onco.cc/institutions/the-christie/), [The Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute](https://onco.cc/institutions/ottawa-hospital/), [Tongji Hospital, Huazhong University of Science and Technology](https://onco.cc/institutions/tongji-hospital-wuhan/), [Uganda Cancer Institute](https://onco.cc/institutions/uganda-cancer-institute/), [UNC Lineberger Comprehensive Cancer Center](https://onco.cc/institutions/unc-lineberger/), [Union Hospital, Tongji Medical College](https://onco.cc/institutions/union-hospital-wuhan/), [University Cancer Center Frankfurt (UCT)](https://onco.cc/institutions/uct-frankfurt/), [University College London Hospitals / UCL Cancer Institute](https://onco.cc/institutions/uclh/), [University Hospital Southampton / Centre for Cancer Immunology](https://onco.cc/institutions/southampton-cancer/), [University Hospital Zurich / Comprehensive Cancer Center Zurich](https://onco.cc/institutions/usz-zurich/), [Wilmot Cancer Institute, University of Rochester](https://onco.cc/institutions/wilmot/)
- pathways: [B-cell receptor / BTK signalling (to NF-κB)](https://onco.cc/pathways/bcr-signalling/), [CD47 / SIRPα (the 'don't eat me' signal)](https://onco.cc/pathways/cd47-sirpa/), [Complement in cancer](https://onco.cc/pathways/complement-in-cancer/), [Intrinsic apoptosis (BCL-2 family)](https://onco.cc/pathways/apoptosis-bcl2/), [MYC](https://onco.cc/pathways/myc/)
- terms: [Anthracyclines (doxorubicin, epirubicin)](https://onco.cc/terms/anthracycline/), [Autologous stem cell transplant (ASCT)](https://onco.cc/terms/autologous-transplant/), [B cell](https://onco.cc/terms/b-cell/), [Cell of origin (GCB vs ABC)](https://onco.cc/terms/cell-of-origin/), [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/), [Deauville five-point scale](https://onco.cc/terms/deauville-score/), [Deauville score and PET-adapted therapy](https://onco.cc/terms/deauville/), [Double-hit / high-grade B-cell lymphoma](https://onco.cc/terms/double-hit-lymphoma/), [Epstein-Barr virus (EBV) in cancer](https://onco.cc/terms/ebv-term/), [ICANS (neurotoxicity)](https://onco.cc/terms/icans/), [International Prognostic Index (IPI)](https://onco.cc/terms/ipi-score/), [Intrathecal therapy (lumbar puncture, Ommaya reservoir)](https://onco.cc/terms/intrathecal-therapy/), [Lugano classification / Ann Arbor staging](https://onco.cc/terms/lugano-classification/), [Lymphoma (tissue type)](https://onco.cc/terms/lymphoma-type/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [MYD88 L265P and CXCR4 mutations](https://onco.cc/terms/myd88-l265p/), [R-CHOP (lymphoma chemoimmunotherapy)](https://onco.cc/terms/r-chop/), [Richter transformation](https://onco.cc/terms/richter-transformation/)
- trials: [A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)](https://onco.cc/trials/nct06890884/), [A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)](https://onco.cc/trials/nct04529772/), [A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies](https://onco.cc/trials/nct05006716/), [A Long-term Extension Study of PCI-32765 (Ibrutinib)](https://onco.cc/trials/nct01804686/), [A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies](https://onco.cc/trials/nct05908409/), [A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma](https://onco.cc/trials/nct06929624/), [A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma](https://onco.cc/trials/nct07011056/), [A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL](https://onco.cc/trials/nct07409428/), [A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL](https://onco.cc/trials/nct06375733/), [A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)](https://onco.cc/trials/nct05192486/), [A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma](https://onco.cc/trials/nct07124936/), [A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL](https://onco.cc/trials/nct05658562/), [A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)](https://onco.cc/trials/nct03162536/), [A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly](https://onco.cc/trials/nct04442022/), [A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies](https://onco.cc/trials/nct07609862/), [A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma](https://onco.cc/trials/nct07189065/), [A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita](https://onco.cc/trials/nct06508658/), [A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas](https://onco.cc/trials/nct04104776/), [A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)](https://onco.cc/trials/nct05406401/), [A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa](https://onco.cc/trials/nct06091865/), [A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr](https://onco.cc/trials/nct05451810/), [A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP](https://onco.cc/trials/nct06828991/), [A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma](https://onco.cc/trials/nct04980222/), [A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma](https://onco.cc/trials/nct07570823/), [A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi](https://onco.cc/trials/nct06717347/), [A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy](https://onco.cc/trials/nct07188558/), [A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China](https://onco.cc/trials/nct07226752/), [AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL](https://onco.cc/trials/nct07215585/), [BELINDA](https://onco.cc/trials/belinda/), [Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL](https://onco.cc/trials/nct04404283/), [Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma](https://onco.cc/trials/nct06829771/), [Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma](https://onco.cc/trials/nct06854445/), [Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL](https://onco.cc/trials/nct06500273/), [DALY II Japan/MB-CART2019.1 for DLBCL](https://onco.cc/trials/nct07288879/), [DALY II USA/ MB-CART2019.1 for DLBCL](https://onco.cc/trials/nct04792489/), [Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma](https://onco.cc/trials/nct07249905/), [DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp](https://onco.cc/trials/nct04920617/), [DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)](https://onco.cc/trials/nct07059650/), [Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients](https://onco.cc/trials/nct04844866/), [Emapalumab Prevention of CAR-T Cell Associated Toxicities](https://onco.cc/trials/nct06550141/), [EPCORE DLBCL-1](https://onco.cc/trials/epcore-dlbcl-1/), [EPCORE DLBCL-2](https://onco.cc/trials/epcore-dlbcl-2/), [EPCORE NHL-1](https://onco.cc/trials/epcore-nhl-1/), [Erythropoietin for Management of Anemia Caused by Chemotherapy](https://onco.cc/trials/nct02890602/), [frontMIND](https://onco.cc/trials/frontmind/), [Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)](https://onco.cc/trials/nct06533579/), [GOLSEEK-1](https://onco.cc/trials/golseek-1/), [IMAGINE (varnimcabtagene autoleucel, Immuneel)](https://onco.cc/trials/imagine-varnimcabtagene/), [Inter-B-NHL Ritux 2010](https://onco.cc/trials/inter-b-nhl-ritux-2010/), [KEYNOTE-170](https://onco.cc/trials/keynote-170/), [L-MIND](https://onco.cc/trials/l-mind/), [LOTIS-2](https://onco.cc/trials/lotis-2/), [Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma](https://onco.cc/trials/nct05326243/), [Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL](https://onco.cc/trials/nct03960840/), [POLARIX](https://onco.cc/trials/polarix/), [Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma](https://onco.cc/trials/nct06220032/), [RELIANCE](https://onco.cc/trials/reliance/), [Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL](https://onco.cc/trials/nct04502394/), [Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)](https://onco.cc/trials/nct04663347/), [Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients](https://onco.cc/trials/nct05222555/), [Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)](https://onco.cc/trials/nct02227251/), [Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma](https://onco.cc/trials/nct05263583/), [STARGLO](https://onco.cc/trials/starglo/), [Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma](https://onco.cc/trials/nct06792253/), [Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL](https://onco.cc/trials/nct05952024/), [Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies](https://onco.cc/trials/nct07284433/), [Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients](https://onco.cc/trials/nct04836507/), [Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL](https://onco.cc/trials/nct06601504/), [Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom](https://onco.cc/trials/nct02952508/), [Study of Out of Specification for Tisagenlecleucel](https://onco.cc/trials/nct04094311/), [Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)](https://onco.cc/trials/nct05563844/), [Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients](https://onco.cc/trials/nct07473167/), [Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma](https://onco.cc/trials/nct02793583/), [Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)](https://onco.cc/trials/nct03936153/), [Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lym](https://onco.cc/trials/nct04384484/), [Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (](https://onco.cc/trials/nct05429268/), [Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer](https://onco.cc/trials/nct01499303/), [Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)](https://onco.cc/trials/nct06395103/), [SUNMO](https://onco.cc/trials/sunmo/), [T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)](https://onco.cc/trials/nct06343311/), [Talicabtagene autoleucel (NexCAR19) phase 1/2](https://onco.cc/trials/talicel-phase-1-2/), [To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL](https://onco.cc/trials/nct04661007/), [TRANSFORM](https://onco.cc/trials/transform/), [Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)](https://onco.cc/trials/nct04542824/), [waveLINE-003](https://onco.cc/trials/waveline-003/), [ZUMA-1](https://onco.cc/trials/zuma-1/), [ZUMA-7](https://onco.cc/trials/zuma-7/)
- journals: [Blood cancer discovery](https://onco.cc/journals/blood-cancer-discovery/), [Blood cancer journal](https://onco.cc/journals/blood-cancer-journal/), [Clinical lymphoma, myeloma & leukemia](https://onco.cc/journals/clinical-lymphoma-myeloma-and-leukemia/), [Current hematologic malignancy reports](https://onco.cc/journals/current-hematologic-malignancy-reports/), [Haematologica](https://onco.cc/journals/haematologica/), [Hematological oncology](https://onco.cc/journals/hematological-oncology/), [Leukemia & lymphoma](https://onco.cc/journals/leukemia-and-lymphoma/)
- ideas: [A funded expert second opinion for every new high-stakes or rare cancer diagnosis](https://onco.cc/ideas/idea-moon-funded-second-opinion/), [A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy](https://onco.cc/ideas/idea-acc-risk-stratified-cardio-oncology-pathway/), [Biomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy](https://onco.cc/ideas/idea-moon-cardioprotection-by-default/), [Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy](https://onco.cc/ideas/idea-reg-early-apheresis-banking/), [ctDNA-guided escalation and de-escalation in frontline DLBCL](https://onco.cc/ideas/idea-ctdna-guided-dlbcl-frontline/), [Head-to-head bispecific vs CAR-T in second-line LBCL](https://onco.cc/ideas/idea-bispecific-vs-car-t-second-line/), [Hospital-based CAR-T manufacturing at cost through a public network](https://onco.cc/ideas/idea-fund-public-car-t-manufacturing/), [Hospital-made CAR-T under one shared regulatory master file](https://onco.cc/ideas/idea-reg-point-of-care-cart-network/), [In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma](https://onco.cc/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/), [In vivo CAR-T manufactured and priced like a generic biologic](https://onco.cc/ideas/idea-moon-in-vivo-cart-generic-price/), [Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route](https://onco.cc/ideas/idea-reg-non-viral-cart-manufacturing/), [Outcome-based annuity payments for potentially curative one-time therapies](https://onco.cc/ideas/idea-fund-pay-for-cure-annuities/), [Pet dogs with spontaneous cancer as a bridge before human trials](https://onco.cc/ideas/idea-bio1-comparative-oncology-dogs/), [Plan the second CAR-T target before the first one is lost](https://onco.cc/ideas/idea-bio1-adaptive-car-antigen-switch/), [Public-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000](https://onco.cc/ideas/idea-reg-lmic-public-cart-manufacturing/), [Read the spinal fluid to track brain tumours without opening the skull](https://onco.cc/ideas/idea-bio2-csf-ctdna-monitoring/), [Turn one tumour into a vaccine to treat all the others](https://onco.cc/ideas/idea-bio2-in-situ-vaccination-solid/), [WHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator](https://onco.cc/ideas/idea-acc-biosimilar-prequalification-pool/)
- people: [Alex F. Herrera](https://onco.cc/people/alex-herrera/), [Armando Santoro](https://onco.cc/people/armando-santoro/), [Ash A. Alizadeh](https://onco.cc/people/ash-alizadeh/), [Carl H. June](https://onco.cc/people/carl-june/), [Catherine Thieblemont](https://onco.cc/people/catherine-thieblemont/), [Christopher R. Flowers](https://onco.cc/people/christopher-flowers/), [Franck Morschhauser](https://onco.cc/people/franck-morschhauser/), [Franco Cavalli](https://onco.cc/people/franco-cavalli/), [Frederick L. Locke](https://onco.cc/people/frederick-locke/), [Gilles Salles](https://onco.cc/people/gilles-salles/), [Hasmukh Jain](https://onco.cc/people/jain-hasmukh/), [Hervé Tilly](https://onco.cc/people/herve-tilly/), [Irving L. Weissman](https://onco.cc/people/irving-weissman/), [Jackson Orem](https://onco.cc/people/jackson-orem/), [Jason R. Westin](https://onco.cc/people/jason-westin/), [Joshua Brody](https://onco.cc/people/joshua-brody/), [Katayoun Rezvani](https://onco.cc/people/katy-rezvani/), [Laurie H. Sehn](https://onco.cc/people/laurie-sehn/), [Lim Soon Thye](https://onco.cc/people/lim-soon-thye/), [Louis M. Staudt](https://onco.cc/people/louis-staudt/), [Michael A. Teitell](https://onco.cc/people/michael-teitell/), [Michael Dickinson](https://onco.cc/people/michael-dickinson/), [Michel Sadelain](https://onco.cc/people/michel-sadelain/), [Peter Johnson](https://onco.cc/people/peter-johnson/), [Ronald Levy](https://onco.cc/people/ronald-levy/), [Sascha Dietrich](https://onco.cc/people/sascha-dietrich/), [Sattva S. Neelapu](https://onco.cc/people/sattva-neelapu/), [Sirpa Leppä](https://onco.cc/people/sirpa-leppa/), [Stanley R. Riddell](https://onco.cc/people/stanley-riddell/), [Stephen J. Forman](https://onco.cc/people/stephen-forman/), [Stephen J. Schuster](https://onco.cc/people/stephen-schuster/), [Steven Le Gouill](https://onco.cc/people/steven-le-gouill/), [Steven T. Rosen](https://onco.cc/people/steven-rosen/), [Vinod Raina](https://onco.cc/people/raina-vinod/), [Wyndham H. Wilson](https://onco.cc/people/wyndham-wilson/), [Yuankai Shi](https://onco.cc/people/shi-yuankai/), [Yuqin Song](https://onco.cc/people/yuqin-song/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/), [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/)
- key papers: [EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T](https://onco.cc/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/), [JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-juliet-tisagenlecleucel-dlbcl-nejm-2019/), [POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/), [Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study](https://onco.cc/key-papers/paper-jain-talicabtagene-lancet-haem-2025/), [TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma](https://onco.cc/key-papers/paper-transform-liso-cel-lancet-2022/), [ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma](https://onco.cc/key-papers/paper-zuma-1-axi-cel-nejm-2017/), [ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early](https://onco.cc/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/)
- biomarkers: [CD19 expression (CD19-positive)](https://onco.cc/biomarkers/cd19-expression/), [CD20 expression (CD20-positive)](https://onco.cc/biomarkers/cd20-expression/)

---
JSON: https://onco.cc/api/v1/entities/dlbcl.json